These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21373780)

  • 1. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease.
    Navarro-Compán V; Moreira V; Ariza-Ariza R; Hernández-Cruz B; Vargas-Lebrón C; Navarro-Sarabia F
    Clin Rheumatol; 2011 Jul; 30(7):993-6. PubMed ID: 21373780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).
    Dougados M; Braun J; Szanto S; Combe B; Elbaz M; Geher P; Thabut G; Leblanc V; Logeart I
    Ann Rheum Dis; 2011 May; 70(5):799-804. PubMed ID: 21317434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.
    Chou CT; Tsai CY; Liang TH; Chang TM; Lai CH; Wei CC; Chen KH; Lin SC; Yu CL; Liou LB; Luo SF; Lee CS; Hsue YT; Huang CM; Chen JH; Lai NS; Cheng HH; Cheng TT; Lai HM; Tsai WC; Yen JH; Lu LY; Chang CP
    Mod Rheumatol; 2010 Dec; 20(6):580-7. PubMed ID: 20683633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept in the longterm treatment of patients with ankylosing spondylitis.
    Dijkmans B; Emery P; Hakala M; Leirisalo-Repo M; Mola EM; Paolozzi L; Salvarani C; Sanmarti R; Sibilia J; Sieper J; Van Den Bosch F; van der Heijde D; van der Linden S; Wajdula J
    J Rheumatol; 2009 Jun; 36(6):1256-64. PubMed ID: 19411393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis.
    Lee J; Noh JW; Hwang JW; Oh JM; Kim H; Ahn JK; Lee YS; Cha HS; Koh EM
    Clin Rheumatol; 2010 Oct; 29(10):1149-54. PubMed ID: 20683738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.
    Lee SH; Lee YA; Hong SJ; Yang HI
    Clin Rheumatol; 2008 Feb; 27(2):179-81. PubMed ID: 17874173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients.
    De Stefano R; Frati E; De Quattro D; Menza L; Manganelli S
    Clin Rheumatol; 2014 May; 33(5):707-11. PubMed ID: 24062201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.
    Baraliakos X; Haibel H; Fritz C; Listing J; Heldmann F; Braun J; Sieper J
    Arthritis Res Ther; 2013; 15(3):R67. PubMed ID: 23786760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
    Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.
    Yates M; Hamilton LE; Elender F; Dean L; Doll H; MacGregor AJ; Thomas J; Gaffney K
    J Rheumatol; 2015 Jul; 42(7):1177-85. PubMed ID: 26034151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis].
    Wang QH; Zhang SZ; Xue J; Wu HX
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):409-14. PubMed ID: 20731042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
    J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.